The genetics of pituitary adenomas

Silvia Vandeva, Marie Lise Jaffrain-Rea, Adrian F. Daly, Maria Tichomirowa, Sabina Zacharieva, Albert Beckers

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Pituitary adenomas are one of the most frequent intracranial tumors with a prevalence of clinically-apparent tumors close to 1:1000 of the general population. They are clinically significant because of hormone overproduction and/or tumor mass effects in addition to the need for neurosurgery, medical therapies and radiotherapy. The majority of pituitary adenomas have a sporadic origin with recognized genetic mutations seldom being found; somatotropinomas are an exception, presenting frequent somatic GNAS mutations. In this and other phenotypes, tumorigenesis could possibly be explained by altered function of genes implicated in cell cycle regulation, growth factors or their receptors, cell-signaling pathways, specific hormonal factors or other molecules with still unclear mechanisms of action. Genetic changes, such as allelic loss or gene amplification, and epigenetic changes, usually by promoter methylation, have been implicated in abnormal gene expression, but alternative mechanisms may be present. Familial cases of pituitary adenomas represent 5% of all pituitary tumors. MEN1 mutations cause multiple endocrine neoplasia type 1 (MEN1), while the Carney complex (CNC) is characterized by mutations in the protein kinase A regulatory subunit-1alpha (PRKAR1A) gene or changes in a locus at 2p16. Recently, a MEN1-like condition, MEN4, was found to be related to mutations in the CDKN1B gene. The clinical entity of familial isolated pituitary adenomas (FIPA) is characterized by genetic defects in the aryl hydrocarbon receptor interacting protein (AIP) gene in about 15% of all kindreds and 50% of homogenous somatotropinoma families. Identification of familial cases of pituitary adenomas is important as these tumors may be more aggressive than their sporadic counterparts.

Original languageEnglish
Pages (from-to)461-476
Number of pages16
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Volume24
Issue number3
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Pituitary Neoplasms
Multiple Endocrine Neoplasia Type 1
Mutation
Genes
Neoplasms
Carney Complex
Gene Amplification
Loss of Heterozygosity
Neurosurgery
Cyclic AMP-Dependent Protein Kinases
Epigenomics
Methylation
Intercellular Signaling Peptides and Proteins
Cell Cycle
Carcinogenesis
Radiotherapy
Hormones
Phenotype
Gene Expression
Population

Keywords

  • AIP
  • Carney complex
  • familial
  • FIPA
  • genetics
  • MEN1
  • pituitary adenoma

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Vandeva, S., Jaffrain-Rea, M. L., Daly, A. F., Tichomirowa, M., Zacharieva, S., & Beckers, A. (2010). The genetics of pituitary adenomas. Best Practice and Research: Clinical Endocrinology and Metabolism, 24(3), 461-476. https://doi.org/10.1016/j.beem.2010.03.001

The genetics of pituitary adenomas. / Vandeva, Silvia; Jaffrain-Rea, Marie Lise; Daly, Adrian F.; Tichomirowa, Maria; Zacharieva, Sabina; Beckers, Albert.

In: Best Practice and Research: Clinical Endocrinology and Metabolism, Vol. 24, No. 3, 06.2010, p. 461-476.

Research output: Contribution to journalArticle

Vandeva, S, Jaffrain-Rea, ML, Daly, AF, Tichomirowa, M, Zacharieva, S & Beckers, A 2010, 'The genetics of pituitary adenomas', Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 24, no. 3, pp. 461-476. https://doi.org/10.1016/j.beem.2010.03.001
Vandeva S, Jaffrain-Rea ML, Daly AF, Tichomirowa M, Zacharieva S, Beckers A. The genetics of pituitary adenomas. Best Practice and Research: Clinical Endocrinology and Metabolism. 2010 Jun;24(3):461-476. https://doi.org/10.1016/j.beem.2010.03.001
Vandeva, Silvia ; Jaffrain-Rea, Marie Lise ; Daly, Adrian F. ; Tichomirowa, Maria ; Zacharieva, Sabina ; Beckers, Albert. / The genetics of pituitary adenomas. In: Best Practice and Research: Clinical Endocrinology and Metabolism. 2010 ; Vol. 24, No. 3. pp. 461-476.
@article{4ee8a7c3f0234102905f60ee52ea0ed3,
title = "The genetics of pituitary adenomas",
abstract = "Pituitary adenomas are one of the most frequent intracranial tumors with a prevalence of clinically-apparent tumors close to 1:1000 of the general population. They are clinically significant because of hormone overproduction and/or tumor mass effects in addition to the need for neurosurgery, medical therapies and radiotherapy. The majority of pituitary adenomas have a sporadic origin with recognized genetic mutations seldom being found; somatotropinomas are an exception, presenting frequent somatic GNAS mutations. In this and other phenotypes, tumorigenesis could possibly be explained by altered function of genes implicated in cell cycle regulation, growth factors or their receptors, cell-signaling pathways, specific hormonal factors or other molecules with still unclear mechanisms of action. Genetic changes, such as allelic loss or gene amplification, and epigenetic changes, usually by promoter methylation, have been implicated in abnormal gene expression, but alternative mechanisms may be present. Familial cases of pituitary adenomas represent 5{\%} of all pituitary tumors. MEN1 mutations cause multiple endocrine neoplasia type 1 (MEN1), while the Carney complex (CNC) is characterized by mutations in the protein kinase A regulatory subunit-1alpha (PRKAR1A) gene or changes in a locus at 2p16. Recently, a MEN1-like condition, MEN4, was found to be related to mutations in the CDKN1B gene. The clinical entity of familial isolated pituitary adenomas (FIPA) is characterized by genetic defects in the aryl hydrocarbon receptor interacting protein (AIP) gene in about 15{\%} of all kindreds and 50{\%} of homogenous somatotropinoma families. Identification of familial cases of pituitary adenomas is important as these tumors may be more aggressive than their sporadic counterparts.",
keywords = "AIP, Carney complex, familial, FIPA, genetics, MEN1, pituitary adenoma",
author = "Silvia Vandeva and Jaffrain-Rea, {Marie Lise} and Daly, {Adrian F.} and Maria Tichomirowa and Sabina Zacharieva and Albert Beckers",
year = "2010",
month = "6",
doi = "10.1016/j.beem.2010.03.001",
language = "English",
volume = "24",
pages = "461--476",
journal = "Best Practice and Research in Clinical Endocrinology and Metabolism",
issn = "1521-690X",
publisher = "Bailliere Tindall Ltd",
number = "3",

}

TY - JOUR

T1 - The genetics of pituitary adenomas

AU - Vandeva, Silvia

AU - Jaffrain-Rea, Marie Lise

AU - Daly, Adrian F.

AU - Tichomirowa, Maria

AU - Zacharieva, Sabina

AU - Beckers, Albert

PY - 2010/6

Y1 - 2010/6

N2 - Pituitary adenomas are one of the most frequent intracranial tumors with a prevalence of clinically-apparent tumors close to 1:1000 of the general population. They are clinically significant because of hormone overproduction and/or tumor mass effects in addition to the need for neurosurgery, medical therapies and radiotherapy. The majority of pituitary adenomas have a sporadic origin with recognized genetic mutations seldom being found; somatotropinomas are an exception, presenting frequent somatic GNAS mutations. In this and other phenotypes, tumorigenesis could possibly be explained by altered function of genes implicated in cell cycle regulation, growth factors or their receptors, cell-signaling pathways, specific hormonal factors or other molecules with still unclear mechanisms of action. Genetic changes, such as allelic loss or gene amplification, and epigenetic changes, usually by promoter methylation, have been implicated in abnormal gene expression, but alternative mechanisms may be present. Familial cases of pituitary adenomas represent 5% of all pituitary tumors. MEN1 mutations cause multiple endocrine neoplasia type 1 (MEN1), while the Carney complex (CNC) is characterized by mutations in the protein kinase A regulatory subunit-1alpha (PRKAR1A) gene or changes in a locus at 2p16. Recently, a MEN1-like condition, MEN4, was found to be related to mutations in the CDKN1B gene. The clinical entity of familial isolated pituitary adenomas (FIPA) is characterized by genetic defects in the aryl hydrocarbon receptor interacting protein (AIP) gene in about 15% of all kindreds and 50% of homogenous somatotropinoma families. Identification of familial cases of pituitary adenomas is important as these tumors may be more aggressive than their sporadic counterparts.

AB - Pituitary adenomas are one of the most frequent intracranial tumors with a prevalence of clinically-apparent tumors close to 1:1000 of the general population. They are clinically significant because of hormone overproduction and/or tumor mass effects in addition to the need for neurosurgery, medical therapies and radiotherapy. The majority of pituitary adenomas have a sporadic origin with recognized genetic mutations seldom being found; somatotropinomas are an exception, presenting frequent somatic GNAS mutations. In this and other phenotypes, tumorigenesis could possibly be explained by altered function of genes implicated in cell cycle regulation, growth factors or their receptors, cell-signaling pathways, specific hormonal factors or other molecules with still unclear mechanisms of action. Genetic changes, such as allelic loss or gene amplification, and epigenetic changes, usually by promoter methylation, have been implicated in abnormal gene expression, but alternative mechanisms may be present. Familial cases of pituitary adenomas represent 5% of all pituitary tumors. MEN1 mutations cause multiple endocrine neoplasia type 1 (MEN1), while the Carney complex (CNC) is characterized by mutations in the protein kinase A regulatory subunit-1alpha (PRKAR1A) gene or changes in a locus at 2p16. Recently, a MEN1-like condition, MEN4, was found to be related to mutations in the CDKN1B gene. The clinical entity of familial isolated pituitary adenomas (FIPA) is characterized by genetic defects in the aryl hydrocarbon receptor interacting protein (AIP) gene in about 15% of all kindreds and 50% of homogenous somatotropinoma families. Identification of familial cases of pituitary adenomas is important as these tumors may be more aggressive than their sporadic counterparts.

KW - AIP

KW - Carney complex

KW - familial

KW - FIPA

KW - genetics

KW - MEN1

KW - pituitary adenoma

UR - http://www.scopus.com/inward/record.url?scp=77956572234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956572234&partnerID=8YFLogxK

U2 - 10.1016/j.beem.2010.03.001

DO - 10.1016/j.beem.2010.03.001

M3 - Article

C2 - 20833337

AN - SCOPUS:77956572234

VL - 24

SP - 461

EP - 476

JO - Best Practice and Research in Clinical Endocrinology and Metabolism

JF - Best Practice and Research in Clinical Endocrinology and Metabolism

SN - 1521-690X

IS - 3

ER -